Delivery Order SPE2DB20D3303-SPE2DB25FA4CC
- Not listed
- The Defense Logistics Agency awarded a competitive delivery order valued at $1,971.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $2,544.36 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 11, 2025. The product will be sourced from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,283.02 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of July 31, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) valued at $1,740.04 under a firm fixed-price contract type. This delivery order, which has an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity, valued at $1,807.02. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The order is scheduled for completion by June 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,278.86 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 180 ml quantities. This contract award is non-set-aside and utilizes firm fixed pricing under a delivery order contract type, with performance scheduled for completion by September 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, with a ceiling value of $3,529.44. The contract, which commenced on September 18, 2025, and concludes by September 19, 2025, employs firm fixed-price pricing and represents a non-set-aside competitive award. AmerisourceBergen's performance location is based in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a contract ceiling value of $2,401.91. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, executed without a set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,334.63 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of May 28, 2025. This is a firm fixed price, non-set-aside delivery order issued under a competitive award process. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 120ml quantity, valued at $1,378.38. The contract, executed on August 19, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 20, 2025. This award carries no set-aside designation, indicating that it was competitively awarded among eligible vendors. The place of performance is AmerisourceBergen's corporate office...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA4CCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $5,223.58 to supply Quillivant XR 25 mg/5 mL suspension in 150 mL quantities. This is a firm fixed price delivery order with an ultimate completion date of September 24, 2025, issued under a non-set-aside competitive procurement. AmerisourceBergen's Corporate Office division, headquartered in Conshohocken, Pennsylvania, will perform the work at that same location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen demonstrates consistent capability to meet Defense Department medical procurement requirements through competitive awards covering diverse therapeutic domains and transaction sizes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 9/23/25 |